Effect of Fuzheng Jiedu Decoction and dumai moxibustion in the treatment of non small cell lung cancer patients in the late stage of lung and spleen deficiency syndrome and the level of immune inflammation
HUANG Kaihong1 WANG Yajun1 LIAN Jianfeng2 DAI Qijun3▲
1.Department of Oncology, Haian Clinical College, Yangzhou University Medical School, Jiangsu Province, Haian 226600, China;
2.Department of Acupuncture, Haian Clinical College, Yangzhou University Medical School, Jiangsu Province, Haian 226600, China;
3.Department of Internal Medicine, Haian Clinical College, Yangzhou University Medical School,Jiangsu Province, Haian 226600, China
Abstract：Objective To explore the effect of Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of non-small cell lung cancer patients in the stage of lung and spleen deficiency syndrome. Methods From January 2020 to January 2022, 82 patients with advanced non-small cell lung cancer admitted to were divided into two groups by random number table method, with 41 cases in each group. The control group was treated with Paclitaxel+Carboplatin, and the study group was treated with dumai moxibustion and Fuzheng Jiedu Decoction on the basis of the control group. After two months of treatment, the scores of traditional Chinese medicine syndromes, levels of immune inflammatory factors (interleukin-6 [IL-6], immunoglobulin A [IgA]) and adverse reactions of the two groups were compared. Results Before treatment, there were no significant differences between the two groups in main syndrome score, secondary syndrome score, IL-6, and IgA (P＞0.05). After treatment, the main syndrome score, secondary syndrome score and IL-6 of the two groups decreased, and the study group was lower than the control group, with a statistically significant difference (P＜0.05). The levels of IgA in the two groups were higher compared with before treatment, and the study group was higher than the control group (P＜0.05). The clinical effect in the study group was better than that in the control group, with a statistically significant difference (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Fuzheng Jiedu Decoction combined with dumai moxibustion in the treatment of advanced non-small cell lung cancer is more helpful for the patients to regulate the expression of immune inflammatory factors, and the clinical effect is superior.
黄开红1 王亚军1 练剑锋2 戴其军3▲. 扶正解毒汤联合督脉灸对肺脾气虚证晚期非小细胞肺癌患者的治疗效果及对免疫炎症水平的影响[J]. 中国医药导报, 2023, 20(22): 128-131.
HUANG Kaihong1 WANG Yajun1 LIAN Jianfeng2 DAI Qijun3▲. Effect of Fuzheng Jiedu Decoction and dumai moxibustion in the treatment of non small cell lung cancer patients in the late stage of lung and spleen deficiency syndrome and the level of immune inflammation. 中国医药导报, 2023, 20(22): 128-131.
京公网安备 11010502046598号